The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Xiaolei Wei; Meng Xu; Yongqiang Wei; Fen Huang; Tong Zhao; Xiangzhao Li; Ru Feng; B. Hilda Ye

doi:10.1186/1756-8722-7-34

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Xiaolei Wei, Meng Xu, Yongqiang Wei, Fen Huang, Tong Zhao, Xiangzhao Li, Ru Feng, B. Hilda Ye

Cell Biology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

Original language	English (US)
Article number	34
Journal	Journal of Hematology and Oncology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/1756-8722-7-34
State	Published - Apr 16 2014

Keywords

Bone marrow involvement
CD44 variant isoforms
CHOP
DLBCL
Prognosis
Rituximab

ASJC Scopus subject areas

Hematology
Molecular Biology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1756-8722-7-34

Cite this

@article{2d00bae219304dc0b4b39031bc3655e1,

title = "The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression",

abstract = "Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.",

keywords = "Bone marrow involvement, CD44 variant isoforms, CHOP, DLBCL, Prognosis, Rituximab",

author = "Xiaolei Wei and Meng Xu and Yongqiang Wei and Fen Huang and Tong Zhao and Xiangzhao Li and Ru Feng and Ye, {B. Hilda}",

note = "Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 81028013), the Science and Technology Project of Guangdong Province of China (Grant No. 2010B050700020), the Science and Technology Project of Guangzhou City (Grant No. 12C22121553), and a pilot grant from CFAR, the Center for AIDS Research at the Albert Einstein College of Medicine.",

year = "2014",

month = apr,

day = "16",

doi = "10.1186/1756-8722-7-34",

language = "English (US)",

volume = "7",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

AU - Wei, Xiaolei

AU - Xu, Meng

AU - Wei, Yongqiang

AU - Huang, Fen

AU - Zhao, Tong

AU - Li, Xiangzhao

AU - Feng, Ru

AU - Ye, B. Hilda

N1 - Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 81028013), the Science and Technology Project of Guangdong Province of China (Grant No. 2010B050700020), the Science and Technology Project of Guangzhou City (Grant No. 12C22121553), and a pilot grant from CFAR, the Center for AIDS Research at the Albert Einstein College of Medicine.

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

AB - Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

KW - Bone marrow involvement

KW - CD44 variant isoforms

KW - CHOP

KW - DLBCL

KW - Prognosis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84899931212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899931212&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-7-34

DO - 10.1186/1756-8722-7-34

M3 - Article

C2 - 24739401

AN - SCOPUS:84899931212

SN - 1756-8722

VL - 7

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 34

ER -

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this